Pfizer, Serum File EUAs For COVID-19 Vaccines In India
Questions Remain Over Serum's Adverse Event
Pfizer and separately Serum Institute, which is partnering Oxford/AstraZeneca's COVID-19 candidate, have filed for emergency use authorizations of their vaccines in India. While Pfizer is yet to conduct clinical trials in India, questions over a serious adverse event during Serum's trials linger despite the regulator's clean chit.
You may also be interested in...
It’s counter-intuitive, but not signing a commercial contract with BioNTech and refusing US federal funding were two of several moves Pfizer made to speed up development of its COVID-19 vaccine, CEO Albert Bourla says. Now it’s looking to supply low- and middle-income countries.
Prices for J&J and Pfizer’s COVID-19 vaccines will be watched closely as India permits private sales. While demand is set to spike with age criteria for those eligible to receive the shots expanded, local manufacturers Serum Institute and Bharat Biotech are ramping up capacities with the government’s help.
Multiple COVID-19 vaccines, including from J&J, Pfizer and RDIF, are seen gaining approvals in India in 2021, following on from a raft of R&D, manufacturing and marketing tie-ups, as well as other developments, in the action-packed field last year.